OUR NEW PROFILE IS: (NASDAQ: INM)
INM has a strong patent position that includes 13 patent families covering manufacturing, methods of use and formulation of rare cannabinoids
As of Sept. 30 Filings the Entire Float at Just 908K shares
INM Exploded Over 50% Yesterday on Record Shattering Interest
International patent application filed for use of rare cannabinoid in treating neuronal disorders
We have another exciting profile for today’s session that we wanted to get in front of you immediately.
Before we dive into today’s profile, I just wanted to do a quick recap of our latest alerts.
Today’s profile moved double digits rather quickly on the heels of exciting spinoff news. Expect more on that later.
Last Thursdays profile opened at $1.17 and hit 1.42 yesterday for a quick 20% or so in just a few sessions.
The Nasdaq alert before that opened at 9.65 and hit 14.79 for potential gains of 53% in just 3 sessions.
The profile before that opened .62 and hit .74 on strong news for a potential 20% move or somewhere in-between.
Moving on we have a company that we want you to research immediately as it has been on the move and on the radar of many traders after several recent significant developments.
Pull up INM right away and start your research.
InMed is developing a pipeline of rare cann-a-binoids across a spectrum of therapeutic applications with large unmet medical needs. The company’s pharmaceutical programs include a Phase 2 clinical trial studying the safety and efficacy of cann-a-binol (CBN) cream for epidermolysis bullosa and preclinical programs in glaucoma and neurodegenerative disease.
InMed is the first company to advance CBN into a clinical trial. CBN is the active pharmaceutical ingredient in two of our pharmaceutical development programs – INM-755 cann-a-binol cream, in Phase 2 clinical development for epidermolysis bullosa, and INM-088 CBN eye drops in preclinical development for glaucoma.
CBN is one of several rare cann-a-binoids found in the Cann-a-bis plant at significantly lower levels relative to the more commonly T-H-C and C-B-D. InMed is exploring the unique physiological effects of CBN, as well as other rare cann-a-binoids, and their therapeutic potential to treat disease.
A Growing Library Of New Cann-a-binoid Analogs.
InMed’s division, BayMedica, has produced an extensive library of cann-a-binoid new chemical entities for pharmaceutical development, aimed at targeting diverse clinical indications. Years of cann-a-binoid research and knowledge has led to a myriad of patentable cann-a-binoid analogs. Its analog patents offer broad protection through its unique molecular components, such as side-chain structures. These cann-a-binoid analogs are suitable for pharmaceutical development.
Rare Cann-a-binoids As Raw Ingredients For The Health And Wellness Industry
InMed’s subsidiary, BayMedica, is manufacturing rare cann-a-binoids for the health and wellness industry. BayMedica is the leading large batch supplier of cannabichromene (CBC) and has recently launched sales of cannabidivarin (CB-DV) and ultra-rare cann-a-binoid, cannabicitran (CBT). Commercial production of tetra-hydro-cannabivarin (TH-CV) is underway and is expected to be available for commercial wholesale soon.
A Diverse Patent Portfolio
InMed has a strong patent position that includes 13 patent families covering manufacturing, methods of use and formulation of rare cann-a-binoids. The company’s portfolio includes a broad patent application for the creation of several variations of novel cann-a-binoid compounds, biosynthetic pathway and semi-synthetic production of both natural cann-a-binoids and analogs, methods for manufacturing and uses of specific rare cann-a-binoids.
Research Partnerships That Strengthen The Company’s Cann-a-binoid Knowledge
InMed’s collaborations with cann-a-binoid experts from around the world ensure we stay at the forefront of rare cann-a-binoid research and development. Their partners play a key role in the development of their programs and share in their pursuit of understanding the biological activity and therapeutic relevance of rare cann-a-binoids and demonstrating the preclinical and clinical evidence that will allow for its safe use.
InMed’s Product Pipeline
VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the first quarter of fiscal year 2023, ended September 30, 2022.
Eric A. Adams, InMed CEO, states, “In the first quarter of our new fiscal year, we continue to strengthen our pharmaceutical pipeline in dermatology, ocular and neurodegenerative diseases, as well as continue to screen our library of proprietary analogs for additional therapeutic candidates. Throughout the remainder of the year and into calendar year 2023, we have many milestones to look forward to in our clinical and preclinical programs, including the completion of our Phase 2 clinical trial in epidermolysis bullosa as well as advancing our glaucoma program towards human trials.”
Pharmaceutical Development Programs
INM-755 for the treatment of Epidermolysis Bullosa (“EB”)
Enrollment and patient treatment in the Company’s Phase 2 clinical trial, 755-201-EB, has continued through the first quarter and is expected to complete during calendar year 2022.
InMed’s Phase 2 clinical trial now has all 11 clinical trial sites fully activated to screen and enroll patients. The clinical trial is taking place in seven countries (Austria, Germany, Greece, France, Italy, Israel and Spain).
InMed is evaluating the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and wound healing in persons with EB over a 28-day treatment period. This study marks the first time cannabinol (“CBN”) has advanced to a Phase 2 clinical trial to be investigated as a therapeutic option to treat a disease.
INM-088 for the treatment of glaucoma
The Company continues to do necessary preclinical work including toxicology and GLP studies in advance of human clinical trials.
Earlier in the year, the Company completed a pre-Investigational New Drug (“pIND”) application discussion with the U.S. Food and Drug Administration (“FDA”) regarding manufacturing, preclinical studies and early clinical development plans for INM-088, a CBN formulation in development for glaucoma. The Company gained alignment with FDA on the design of the initial Phase 1-2 clinical trial to gather preliminary data on the safety and efficacy of INM-088 treatment.
InMed data suggest CBN is the cannabinoid of choice for neuroprotection and lowering intraocular pressure in glaucoma and potentially other ocular diseases.
New cannabinoid analogs for the treatment of neurodegenerative diseases
The Company continues to advance discovery work to identify an appropriate compound for a preclinical development program for treating neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease.
The Company remains focused on the generation of proprietary cannabinoid analogs to support its pharmaceutical drug development programs. As these novel cannabinoid analogs are patentable, they protect the long-term research investment and commercial opportunities.
BayMedica commercial activities
BayMedica commercial activities remain steady as the Company continues to work through existing inventories as a B2B supplier of rare cannabinoids to the health and wellness market. The Company continues to explore potential opportunities for structured supply agreements, commercial collaborations and review other strategic alternatives for the commercial aspect of its business.
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding
- Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s
- Identified two lead cannabinoid analog compounds for in vivo studies
- NSERC grant funding supports InMed’s collaborative research projects with Dr. Kumar from University of British Columbia (UBC)
VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the launch of its neurodegenerative disease program (INM-900 series), which will be investigating the effects of cannabinoid analogs in diseases such as Alzheimer’s, Huntington’s and Parkinson’s.
In research conducted to date, InMed has identified two cannabinoid analogs demonstrating promising effects related to the treatment of neurodegenerative diseases, warranting further investigation in in vivo studies. InMed will be conducting studies using in vivo models in neurodegenerative disease to select the most appropriate candidate for clinical studies. Early preclinical efficacy readout is expected in 2Q 2023.
In addition, Dr. Ujendra Kumar of the faculty of Pharmaceuticals Sciences at UBC has been awarded an Alliance grant from NSERC, with InMed as the named industry partner. The funding will support the research and development studies of InMed’s cannabinoid pharmaceutical candidates, investigating their potential therapeutic effects in neurodegenerative diseases. The collaboration project is entitled “Pharmacological characterization of phytocannabinoids and the endocannabinoid system.”
InMed’s Senior Vice President of Preclinical Research & Development, Eric Hsu, Ph.D., commented, “We are pleased that our efforts have led to the identification of two cannabinoid analog candidates to advance to in vivostudies. Our team will continue this important research in neurodegenerative diseases under the NSERC Alliance grant. Our early studies are showing promising neuroprotective effects as well as neurite outgrowth, signifying the potential to enhance neuronal function that may be important in the treatment of neurodegenerative diseases. This program, in conjunction with the work we are doing within glaucoma, increases our focus on, and expands our pipeline within, the neuroprotection space.”
In December 2021, InMed filed an international patent application demonstrating neuroprotection and enhanced neuronal function using rare cannabinoids and analogs for the potential treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others. The patent specifies such compounds that may inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection in a population of affected neurons.
Why pursue cannabinoid analogs?
Unlike natural cannabinoids isolated from the plant which are not patentable, these cannabinoid analogs are patentable. Benefits may include:
- Targeting certain physiological outcomes in specific diseases;
- Improving upon the safety profile of the natural cannabinoids;
- Enhancing the ability to integrate with specific delivery technologies; and
- Protecting the long-term research investment and commercial opportunities.
About InMed: InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com and www.baymedica.com.
Eric A. Adams, MIBS
Chief Executive Officer & President
Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than $35M in
Michael Woudenberg, P.Eng.
Chief Operating Officer
Mr. Woudenberg joined InMed with more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He brings valuable expertise in the development, technology transfer and commercialization of
Alexandra D.J. Mancini, MSc
Senior Vice President, Clinical & Regulatory Affairs
Ms. Mancini has more than 30 years of global biopharmaceutical R&D experience, overseeing a wide range of drug development activities, with a particular emphasis on clinical development and regulatory affairs. She has been an executive with numerous biotech